Previous and potential mutations of Sars-cov-2 receptors and their interaction with known inhibitors
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Chukwuemeka Odumegwu Ojukwu University Igbariam, Anambra State, Nigeria.
2 Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Chukwuemeka Odumegwu Ojukwu University Igbariam, Anambra State, Nigeria.
3 Department of Pharmacognosy and Traditional Medicine, Faculty of Pharmaceutical Sciences, Chukwuemeka Odumegwu Ojukwu University Igbariam, Anambra State, Nigeria.
4 Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University Awka, Anambra State, Nigeria.
Review Article
GSC Biological and Pharmaceutical Sciences, 2023, 24(03), 234–246.
Article DOI: 10.30574/gscbps.2023.24.3.0374
Publication history:
Received on 02 August 2023; revised on 13 September 2023; accepted on 15 September 2023
Abstract:
SARS-CoV-2, the seventh coronavirus known to infect humans after 229E, NL63, 0C43, HKU1, MERS-CoV, and the original SARS-CoV, has a large positive-stranded RNA genome of 29,891 nucleotides and 9,860 amino acids. It is a strain of coronavirus that causes COVID 19. It was first discovered in the Chinese city of Wuhan. It undergoes several mutations hence posing a great difficulty in finding a suitable inhibitor. This studies previous and potential mutations of Sars-cov-2 receptors and their interaction with known inhibitors. There are four measures to take in generating SARS-CoV-2 inhibitors that might surpass mutation should it arise which includes; a. finding inhibitors with two or more mechanism of inhibition in virus target inhibition b. employing host target inhibition c. complex forming compounds that will interfere with viral-host cell fusion independent of interaction with the host or organism d. human receptor cell lookalikes with higher affinity to the virus (proteins). Employing any of these measures might produce a good inhibitor however, drug resistance may emerge quickly after treatment as a result of the numerous mutations that RNA virus experience but host cell mutations are uncommon, treatments that target the host cells may delay the emergence of drug resistance.
Keywords:
SARS-CoV-2; Inhibition; Mutation; Drug resistance; Receptors
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
